Long-term treatment with Ultomiris (ravulizumab) reduced the risk of death by five times in people with paroxysmal nocturnal hemoglobinuria (PNH), and also tended to eliminate the need for blood transfusions and to improve patients’ quality of life, a new analysis suggests. The findings were detailed in the study,…
News
Voydeya (danicopan) effectively and safely treated paroxysmal nocturnal hemoglobinuria (PNH) in people with significant extravascular hemolysis, when used as an add-on therapy to Ultomiris (ravulizumab) or Soliris (eculizumab). That’s according to long-term data from the Phase 3 ALPHA trial (NCT04469465), which found that dual treatment with…
Fatigue affects the ability of adults with paroxysmal nocturnal hemoglobinuria (PNH) to perform daily tasks, interact socially, and stay focused, even with treatment, showing how the disease limits physical, emotional, and social well-being, according to a real-world study. The findings indicate how the impact on health-related quality of life…
Samsung Bioepis has partnered with Teva Pharmaceuticals to commercialize the Soliris (eculizumab) biosimilar Epysqli (eculizumab-aagh) in the U.S. for people with paroxysmal nocturnal hemoglobinuria (PNH). A biosimilar is a biological product with an active ingredient that is highly similar to an already approved biological medicine, known as…
A novel combination of pozelimab and cemdisiran appears to be better than Ultomiris (ravulizumab) at controlling intravascular hemolysis — the rupture of red blood cells inside blood vessels — in adults with paroxysmal nocturnal hemoglobinuria (PNH), showing promise as a potential treatment for the rare acquired disease. That’s…
Patients with paroxysmal nocturnal hemoglobinuria (PNH) in 53 countries with limited access to life-saving treatments will be able to receive treatment with Fabhalta (iptacopan). The Max Foundation, a global nonprofit organization, and Novartis are expanding their collaboration to address the unmet needs of patients across Sub-Saharan…
Six months of twice-daily treatment with oral Fabhalta (iptacopan) improved hemoglobin levels in adults with paroxysmal nocturnal hemoglobinuria (PNH) who switched from standard anti-C5 therapies, according to top-line results from a Phase 3 clinical trial. Dubbed APPULSE-PNH (NCT05630001), the now-complete study tested Novartis’ therapy in 52…
Note: This story was updated Dec. 6, 2024, to correct that Voydeya is approved as an add-on treatment to standard PNH therapies to help control extravascular hemolysis. The headline was changed to clarify that these were the results of a review study. Voydeya (danicopan) — whether given as a…
Omeros’ zaltenibart (OMS906) as a single therapy has shown promise as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) in a small clinical study, normalizing signs of hemolysis, or red blood cell destruction, in adults with hard-to-treat disease, according to new interim data. The trial enrolled PNH patients who…
Treatment with Ultomiris (ravulizumab) successfully reduced multiple blood clots that didn’t respond to standard anti-clotting therapy in a woman with paroxysmal nocturnal hemoglobinuria (PNH), a case study shows. “This report presents a case of myocardial and renal infarction [heart and kidney tissue death due to blood supply obstruction]…
Recent Posts
- Real-world study: Ultomiris is preferred treatment option for PNH
- New questionnaire assessing fatigue ‘reliable and valid’ for adults with PNH
- Progress in research and treatments is a reason for holding on to hope
- New gene study highlights clot risk factor in people living with PNH
- Becoming a patient advocate gave me purpose in the fight against PNH